Damora Therapeutics (DMRA) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Oct 27, 2026

Net buying: insiders sold $0 and bought $253K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: +$253K netNet buying
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 4 added, 1 cutMore adding
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about DMRA filings

Are insiders buying or selling Damora Therapeutics, Inc. (DMRA) stock?

Net buying: insiders sold $0 and bought $253K of DMRA stock on the open market in the 90 days to Oct 27, 2026, according to SEC Form 4 filings. The largest was Jarrett, Jennifer (Director, President and CEO), who bought $253K. The latest filing was on Sep 28, 2026.

Which members of Congress have traded DMRA recently?

None. No member of Congress disclosed a DMRA trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this DMRA smart-money data?

This summary uses filings available on Oct 27, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on DMRA

Lean long1 source:
- Funds
Neutral1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
- Garrett Winslow, sold $7.3K, scheduled plan sale, filed Jul 8
- Jennifer Jarrett, bought $253K, open market, filed Sep 28
Neutral · thin1 buy · 1 sale
1 of 2 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
Lean long2 added · 1 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about DMRA filings

Are insiders buying or selling Damora Therapeutics, Inc. (DMRA) stock?

Net buying: insiders sold $0 and bought $253K of DMRA stock on the open market in the 90 days to Oct 27, 2026, according to SEC Form 4 filings. The largest was Jarrett, Jennifer (Director, President and CEO), who bought $253K. The latest filing was on Sep 28, 2026.

Which members of Congress have traded DMRA recently?

None. No member of Congress disclosed a DMRA trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this DMRA smart-money data?

This summary uses filings available on Oct 27, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Funds

What funds are doing

8 moves · 6 mo

Buys/Adds$516.6MSells/Trims$29.6M

Buys/Adds (2)

VG
Viking Global
Andreas Halvorsen · Q2 2026 13F
$60.1M
bought
Signals like this: n=3224, 54% finished lower at D15, median -0.8% vs SPY -0.4%
JC
JPMorgan Chase
Q2 2026 13F
$49.8M
bought

Sells/Trims (1)

P7
Point72
Steven Cohen · Q2 2026 13F
$29.6M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%

5 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 5 moves

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 10, 2026

Earnings came in 5.4% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 10, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.39-5.41% miss

-$0.37 expected

Revenue

$0.00

SEC filing · No operating revenue

EPS: Yahoo Finance

Next report

Estimated report: Nov 5, 2026, in 9 days

Previous reports

Period ending	Reported	EPS / estimate	EPS surprise	Revenue / income	Surprise
Jun 30, 2026	Aug 10, 2026	-$0.39 / -$0.37Yahoo Finance	-5.41% miss	$0.00 No estimateSEC filing · No operating revenue	Unavailable
Mar 31, 2026	May 12, 2026	-$0.81 / -$0.65Alpha Vantage	-24.62% miss	Unavailable	Unavailable
Dec 31, 2025	Mar 18, 2026	$2.31 / -$0.11Alpha Vantage	+$2.41 beat	Unavailable	Unavailable
Sep 30, 2025	Nov 7, 2025	Unavailable	-	$0.00 No estimate	Unavailable
Jun 30, 2025	Aug 6, 2025	Unavailable	-	Unavailable	Unavailable
Mar 31, 2025	May 9, 2025	Unavailable	-	Unavailable	Unavailable
Dec 31, 2024	Mar 19, 2025	-$5.00 / -$2.82Alpha Vantage	-77.31% miss	Unavailable	Unavailable
Sep 30, 2024	Nov 1, 2024	-$3.39 / -$3.70Alpha Vantage	+8.38% beat	Unavailable	Unavailable

EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.

Open: $21.19
52-wk high: $38.33
High: $21.78
52-wk low: $4.95
Low: $21.09
Prev close: $21.09
Mkt cap: $1.30B
ROE: -99.7%
Beta: 1.44
P/B: 4.5x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $1.3B

Valuation

P/B4.54

Quality

Operating margin0.0%
ROE-99.7%
ROA-21.6%

Growth

Beta1.44

Technicals

Price structure

This stock's price action is mixed.

Trend

Mixed

55 / 100

RSI 14

60balanced

20D volatility

60%annualized

52-week range

$21.26

$4.95$38.33

20D support

$17.49recent floor

20D resistance

$22.68recent ceiling

Returns

5D +10.3%20D +2.5%60D -26.7%

Price vs moving averages

SMA20 +5.1%SMA50 -12.5%SMA200 -17.2%

Volume pace

0.59xvs prior 20D

Damora Therapeutics, Inc.

Smart money at a glance

What do analysts expect?

Questions about DMRA filings

Smart money on DMRA

Questions about DMRA filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 5.4% below what analysts expected.

Estimated report: Nov 5, 2026, in 9 days

Previous reports

Is the business strong?

Price structure

Damora Therapeutics, Inc.

Smart money at a glance

What do analysts expect?

Questions about DMRA filings

Smart money on DMRA

Questions about DMRA filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 5.4% below what analysts expected.

Estimated report: Nov 5, 2026, in 9 days

Previous reports

Is the business strong?

Price structure

Damora Therapeutics, Inc.

Overview

Questions about DMRA filings

Smart money

Unlock everything for $29/month

Earnings

Financials

Technicals

Damora Therapeutics, Inc.

Overview

Questions about DMRA filings

Smart money

Unlock everything for $29/month

Earnings

Financials

Technicals